Open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis : a systematic review and meta-analysis
Journal of Clinical Microbiology · 12.08.2026 · 64 (8)
DOI: 10.1128/jcm.00321-26 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Clinical Microbiology, erschienen am 12.08.2026. Verfasst von Klaas Dewaele und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Mycobacteriology, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Antitubercular Agents, Drug Resistance, Bacterial, Software. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Whole-genome sequencing (WGS) accelerates drug-susceptibility testing (DST) in Mycobacterium tuberculosis (Mtb). Open-access software tools have become widely available, but the sources of real-world performance variability remain uncharacterized. We performed a systematic review and meta-analysis of the performance of open-access, independently validated WGS-based DST prediction tools. Bivariate random-effects meta-analysis was performed for six maintained tools (TBProfiler, Mykrobe, PhyResSE, MTBseq, GenTB, and SAM-TB). Bivariate meta-regression identified covariates associated with performance variation. Thirty-nine studies comprising 144,623 genomes were included. For the two most extensively validated tools, TBProfiler and Mykrobe, pooled rifampicin sensitivity was 95.4% (95% CI: 93.5–96.7) and 93.7% (92.0–95.1), with a specificity of 97.3% (95.7–98.3) and 97.0% (94.8–98.3), respectively. For isoniazid, the sensitivity was 92.0% (90.4–93.3) and 88.2% (85.5–90.4) and specificity 97.3% (96.0–98.2) and 97.5% (95.8–98.5). For ethambutol, the specificity was heterogeneous across tools (86.5%–95.4%); for pyrazinamide, the sensitivity varied widely (49.9%–80.6%). For fluoroquinolones, both sensitivity and specificity approached 90%, with heterogeneity. For newer agents, data scarcity precluded meaningful assessment. Meta-regression identified rifampicin resistance prevalence as the dominant predictor of decreased specificity across first-line drugs (β −1.5 to −3.6 on logit scale, false discovery rate [FDR] q < 0.05), while lineage composition effects were small and confounded. Current open-access WGS prediction tools achieve clinically useful accuracy as rule-out tests for rifampicin, isoniazid, and fluoroquinolone resistance. Predictive performance for second-line drugs is limited by data scarcity. Methodological limitations, including lineage bias, data leakage, and selective sampling, may undermine the tools’ generalizability across diverse global tuberculosis populations. IMPORTANCE Tuberculosis remains a leading infectious disease killer worldwide. Whole-genome sequencing (WGS) of Mycobacterium tuberculosis offers the potential to rapidly predict drug resistance as a one-stop test, but the accuracy of the software tools used to interpret sequencing results has been inconsistently reported. This meta-analysis leverages the heterogeneity across 39 studies and 144,623 genomes to identify factors that drive inconsistencies in reported performance, providing context-specific guidance for clinical adoption. We show that most tools perform adequately as rule-out tests for resistance to the most important first- and second-line drugs but fall short of specificity targets. Importantly, we identify that the local burden of drug resistance in a study population is the dominant factor driving inconsistencies between reported performance estimates. These findings provide guidance for laboratories considering adopting sequencing-based resistance testing and specify priorities for future tool development and validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Mycobacteriology, Institute of Tropical Medicine, Antwerp, Belgium.
- Unit of HIV and Tuberculosis, Institute of Tropical Medicine, Antwerp, Belgium.
- Molecular Diagnostic and Research Group, Université de Yaoundé, Yaoundé, Cameroon.
- Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
- Clinical Department of Laboratory Medicine and National Reference Center for Respiratory Pathogens, KU Leuven University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Klaas Dewaele
Zitieren
APA
Dewaele, K., Jouego, C., Asim, A., Laenen, L., Meehan, C., & André, E. (2026). Open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis : a systematic review and meta-analysis. Journal of Clinical Microbiology, 64(8). https://doi.org/10.1128/jcm.00321-26
Vancouver
Dewaele K, Jouego C, Asim A, Laenen L, Meehan C, André E. Open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis : a systematic review and meta-analysis. Journal of Clinical Microbiology. 2026;64(8). doi:10.1128/jcm.00321-26
BibTeX
@article{Dewaele2026,
author = {Dewaele, Klaas and Jouego, Christelle and Asim, Adina and Laenen, Lies and Meehan, Conor and André, Emmanuel},
title = {Open-access genomic drug resistance prediction tools for Mycobacterium tuberculosis : a systematic review and meta-analysis},
journal = {Journal of Clinical Microbiology},
year = {2026},
volume = {64},
number = {8},
doi = {10.1128/jcm.00321-26}
}
EUVIMED